A Phase II, Single‐Arm, Open‐Label, Bayesian Adaptive Efficacy and Safety Study of PBI‐05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma

LESSONS LEARNED: This trial evaluating a novel plant extract, PBI‐05204, did not meet its primary endpoint of overall survival but did show signals of efficacy in heavily pretreated mPDA. PBI‐05204 was generally well tolerated, with the most common side effects related to treatment being vomiting (2...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Roth, Marc T., Cardin, Dana Backlund, Borazanci, Erkut Hasan, Steinbach, Margaux, Picozzi, Vincent J., Rosemury, Alexander, Wadlow, Raymond Couric, Newman, Robert A., Berlin, Jordan
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Inc. 2020
נושאים:
Clinical Trial Results
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543353/
https://ncbi.nlm.nih.gov/pubmed/32452588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0440
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים